Research map: Cascading Attrition of In Vivo CAR-T Therapy: From Systemic Delivery Failure to Functional Collapse

Back to the article

Papers in this map

  1. Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability · Katalin Karikó · 2008 · 1958 citations · Cited by this paper
  2. TROP-2 in solid tumors: From oncogenic driver to therapeutic target with antibody-drug conjugates · 2026 · Related
  3. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection · Justin Eyquem · 2017 · 1888 citations · Cited by this paper
  4. Circulating tumour DNA and molecular residual disease in oesophageal cancer: Clinical readiness, evidence gaps and trial-ready applications · 2026 · Related
  5. Nanoparticle biointerfacing by platelet membrane cloaking · Che‐Ming Jack Hu · 2015 · 1814 citations · Cited by this paper
  6. Molecular mechanisms of targeted therapy in breast cancer: An integrated signaling network perspective · 2026 · Related
  7. Long-term outcomes following CAR T cell therapy: what we know so far · Kathryn M. Cappell · 2023 · 1414 citations · Cited by this paper
  8. In vivo engineering of CAR-T cells: delivery strategies and clinical translation · 2026 · Related
  9. Viral vector platforms within the gene therapy landscape · Jote Bulcha · 2021 · 1394 citations · Cited by this paper
  10. The adipose microenvironment in colorectal cancer: Navigating the nexus of inflammation, metabolism, and metastatic reprogramming · 2026 · Related
  11. CAR T cells produced in vivo to treat cardiac injury · Joel G. Rurik · 2022 · 1357 citations · Cited by this paper
  12. Biomimetic nanoparticles for metastatic breast cancer: Advancing targeted drug delivery beyond conventional nanomedicine · 2026 · Related
  13. Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers · Susanne Schöttler · 2016 · 1269 citations · Cited by this paper
  14. In vivo CAR cell therapy: from bench to bedside · 2025 · Related
  15. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up · Fabian Müller · 2024 · 1085 citations · Cited by this paper
  16. From Ex Vivo to In Vivo : Advances in Lentiviral Vector Engineering for CAR-T Therapy · 2026 · Related
  17. Minimal "Self" Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles · Pia L. Rodriguez · 2013 · 990 citations · Cited by this paper
  18. Tonic signaling in CAR-T therapy: the lever long enough to move the planet · 2025 · Related
  19. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines · Kimberly J. Hassett · 2019 · 939 citations · Cited by this paper
  20. In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies · 2025 · Related
  21. A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates · Staci Sabnis · 2018 · 829 citations · Cited by this paper
  22. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs · Sean A. Dilliard · 2023 · 681 citations · Cited by this paper
  23. Intrinsic antiviral immunity · Nan Yan · 2012 · 540 citations · Cited by this paper
  24. The dose threshold for nanoparticle tumour delivery · Ben Ouyang · 2020 · 520 citations · Cited by this paper
  25. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy · Yan Zong · 2023 · 481 citations · Cited by this paper
  26. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products · Mohamed Yousif Ibrahim · 2022 · 461 citations · Cited by this paper
  27. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics · Yeji Lee · 2023 · 449 citations · Cited by this paper
  28. Microfluidic formulation of nanoparticles for biomedical applications · Sarah J. Shepherd · 2021 · 436 citations · Cited by this paper
  29. Cloaking nanoparticles with protein corona shield for targeted drug delivery · Jun Yong Oh · 2018 · 414 citations · Cited by this paper
  30. The Capsids of HIV-1 and HIV-2 Determine Immune Detection of the Viral cDNA by the Innate Sensor cGAS in Dendritic Cells · Xavier Lahaye · 2013 · 403 citations · Cited by this paper
  31. Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery · Yan Fang · 2017 · 387 citations · Cited by this paper
  32. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver · Lei Miao · 2020 · 344 citations · Cited by this paper
  33. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+T-cells · Benjamin Descours · 2012 · 338 citations · Cited by this paper
  34. Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics · Carla B. Roces · 2020 · 324 citations · Cited by this paper
  35. In vivo CAR T cell generation to treat cancer and autoimmune disease · Theresa Hunter · 2025 · 323 citations · Cited by this paper
  36. Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy · Mohamed Abou‐El‐Enein · 2021 · 321 citations · Cited by this paper
  37. Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems · Masatoshi Maeki · 2018 · 318 citations · Cited by this paper
  38. Margination of micro- and nano-particles in blood flow and its effect on drug delivery · Kathrin Müller · 2014 · 314 citations · Cited by this paper
  39. Immunogenicity of CAR T cells in cancer therapy · Dimitrios L. Wagner · 2021 · 313 citations · Cited by this paper

Source: OpenAlex (CC0)